Polaryx Therapeutics, Inc.

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Founded in 2014, the company's mission is to address the significant unmet medical needs and accelerate the availability of treatments for patients and families affected by these conditions, adopting a patient-first approach in its research and development process. Polaryx Therapeutics is headquartered in Paramus, New Jersey, United States.

The company's therapeutic strategy involves developing patient-friendly small molecule and gene therapy treatments that aim to promote lysosome biogenesis via PPARα-dependent TFEB upregulation, attenuate inflammation in the brain, and enhance neuronal survival. Its pipeline includes several candidates: PLX-200, PLX-300, PLX-100 (small molecule therapies), and PLX-400 (a gene therapy candidate). PLX-200 is the most advanced drug candidate, a repurposed oral small molecule being developed through a 505(b)(2) regulatory pathway. It has received multiple FDA Orphan Drug Designations and Fast Track Designations for various indications within LSDs, including neuronal ceroid lipofuscinoses (CLN2, CLN3), Krabbe disease, and GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases).

Alex Yang, J.D., LL.M., serves as the CEO and Chair of the Board. Polaryx Therapeutics completed a direct listing on the Nasdaq Capital Market under the ticker symbol PLYX on February 2, 2026. The company plans to initiate the SOTERIA Phase 2 basket trial in the first half of 2026 to evaluate PLX-200 across multiple LSDs, including CLN2, CLN3, Krabbe, and Sandhoff diseases, having received FDA Fast Track Designations for all four indications. As a clinical-stage biotechnology company, Polaryx Therapeutics currently generates no revenue from product sales, with its valuation significantly dependent on the outcomes of future clinical trials and regulatory approvals.